Shalby grants 4,000 ESOPs at ₹100 per option

1 min read     Updated on 28 May 2026, 04:20 AM
scanx
Reviewed by
Naman SScanX News Team
AI Summary

Shalby Limited granted 4,000 stock options to an eligible employee under its ESOP Scheme 2021 at an exercise price of ₹100 per option. The options vest after two years and must be exercised within one year of vesting. The shares will be sourced from the secondary market, resulting in no increase in the company's share capital.

powered bylight_fuzz_icon
41467802

*this image is generated using AI for illustrative purposes only.

Shalby Limited has granted 4,000 stock options to an eligible employee under its Shalby Limited Employees Stock Options Scheme – 2021. The Nomination and Remuneration Committee approved the grant on May 27, 2026. The options are convertible into an equal number of equity shares with a face value of ₹10 each. The exercise price for these options has been determined at ₹100 per option.

The options granted are sourced from a pool of lapsed options. The scheme is administered by the Nomination and Remuneration Committee and is in compliance with the SEBI (SBEB & SE) Regulations, 2021. The grant is based on eligibility criteria including individual performance, target achievement, and functional performance.

The granted options will vest after the completion of two years from the date of grant. Once vested, the options must be exercised wholly within a period of one year from the date of vesting. The entitlement to acquire shares is subject to the payment of the exercise price and applicable taxes, along with continued employment at the time of vesting.

The total number of shares arising from the exercise of these options will be 4,000 equity shares. The company stated that its share capital will not increase as a result of this exercise, as the shares are channelized from the secondary market. The exercise price is determined based on the average purchase price of the shares acquired by the trust or the market price, with the committee holding the power to provide a discount or charge a premium.

Particulars Details
Options Granted 4,000
Face Value ₹10 per share
Exercise Price ₹100 per option
Vesting Period 2 years from date of grant
Exercise Period 1 year from date of vesting

Historical Stock Returns for Shalby

1 Day5 Days1 Month6 Months1 Year5 Years
-2.04%+1.24%+1.34%-19.53%-15.64%+0.96%

Will Shalby Limited expand the pool of lapsed options to accommodate future grants under the ESOS scheme?

How might the vesting cliff structure impact employee retention rates over the next two years?

Does the company plan to increase the volume of stock options granted to a wider employee base in the future?

Shalby Limited Schedules Earnings Conference Call to Discuss Q4FY26 Results on May 29, 2026

1 min read     Updated on 18 May 2026, 03:46 PM
scanx
Reviewed by
Shriram SScanX News Team
AI Summary

Shalby Limited has scheduled an Earnings Conference Call for Friday, May 29, 2026, at 5:00 PM IST, to discuss Q4 FY2026 earnings, in compliance with Regulation 30 of SEBI LODR Regulations, 2015. The call, hosted by Elara Securities (India) Private Limited, will be attended by senior leadership including the Chairman and Managing Director, CFO, and other key executives. Dial-in access is available across multiple geographies, including toll-free numbers for the US, UK, Singapore, Hong Kong, and Australia. The disclosure was filed with both NSE and BSE on May 18, 2026.

powered bylight_fuzz_icon
40644963

*this image is generated using AI for illustrative purposes only.

Shalby Limited has announced an Earnings Conference Call to discuss its Q4 FY2026 financial results. The announcement, made pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, was communicated to both the National Stock Exchange of India Ltd and BSE Limited on May 18, 2026. The conference call is scheduled for Friday, May 29, 2026, at 5:00 PM IST, and will be hosted by Elara Securities (India) Private Limited.

Senior Leadership to Represent the Company

The earnings call will feature a distinguished panel of senior executives from Shalby Limited. The key representatives scheduled to participate are outlined below:

Role Representative
Chairman and Managing Director Dr. Vikram Shah
President Mr. Shanay Shah
COO, Shalby Hospitals Dr. Nishita Shukla
CEO, Shalby MedTech Mr. Deepak Anand
CFO Mr. Amit Kumar
CHRO Mr. Babu Thomas
IRCS Mr. Jigar Todi

Conference Call Access Details

Participants can join the call through multiple dial-in options across geographies. The following access numbers have been provided:

Region Dial-In Number
Universal (India) +91 22 6280 1146
Universal (India) +91 22 7115 8047
Toll Free – US 1 866 746 2133
Toll Free – UK 0 808 101 1573
Toll Free – Singapore 800 101 2045
Toll Free – Hong Kong 800 964 448
Toll Free – Australia 0080014243444

The call timings across key international time zones are as follows:

  • 12:30 PM – United Kingdom
  • 7:30 PM – Singapore and Hong Kong
  • 7:30 AM – East Coast, US
  • 4:30 AM – West Coast, US

Participants may also register via the Diamond Pass Login link provided in the official invite. For RSVPs and further queries, participants can contact Dr. Bino Pathiparampil at Elara Capital via email at bino.pathiparampil@elaracapital.com or by phone at +91 22 6164 8689.

Regulatory Compliance

The disclosure was signed by Tushar Shah, Vice President & Company Secretary (Membership No. F7216), on behalf of Shalby Limited. The communication was submitted to both stock exchanges in accordance with applicable SEBI listing regulations, affirming the company's adherence to its disclosure obligations.

Historical Stock Returns for Shalby

1 Day5 Days1 Month6 Months1 Year5 Years
-2.04%+1.24%+1.34%-19.53%-15.64%+0.96%

What key financial metrics and guidance for FY2027 is Shalby Limited expected to reveal during the Q4 FY2026 earnings call?

How might Shalby MedTech's performance in Q4 FY2026 signal the company's strategic pivot toward medical technology and its contribution to future revenue diversification?

Given the presence of both hospital operations (COO) and MedTech (CEO) leadership on the call, could Shalby be planning a structural reorganization or separate listing of its MedTech division?

More News on Shalby

1 Year Returns:-15.64%